Immunomodulatory effects in a phase II study of lenalidomide combined with cetuximab in refractory KRAS-mutant metastatic colorectal cancer patients

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Gandhi, Anita K ^a   Shi, Tao ^a   Li, Mingyu ^a   Jungnelius, Ulf ^b   Romano, Alfredo ^b   Tabernero, Josep ^c   Siena, Salvatore ^d   Schafer, Peter H ^a   Chopra, Rajesh ^a  

^a CELGENE CORPORATION   (United States)

^b Clinical Research and Development   (United States)

^c VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^d OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD45RA ANTIGEN; CD45RO ANTIGEN; CD8 ANTIGEN; CETUXIMAB; HLA DR ANTIGEN; LENALIDOMIDE; ANTINEOPLASTIC AGENT; KRAS PROTEIN, HUMAN; MONOCLONAL ANTIBODY; ONCOPROTEIN; RAS PROTEIN; THALIDOMIDE;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG ACTIVITY; FEMALE; GENE MUTATION; HELPER CELL; HUMAN; IMMUNOMODULATION; IMMUNOSTIMULATION; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; MAJOR CLINICAL STUDY; MALE; MEMORY T LYMPHOCYTE; METASTATIC COLORECTAL CANCER; MULTICENTER STUDY; NATURAL KILLER CELL; ONCOGENE K RAS; OPEN STUDY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TUMOR IMMUNITY; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COLORECTAL NEOPLASMS; GENETICS; IMMUNOLOGY; MUTATION;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; HUMANS; MUTATION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; THALIDOMIDE;

EID: 84892740595     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080437     Document Type: Article

References (23)

1. Ito T, Ando H, Suzuki T, Ogura T, Hotta K, et al. (2010) Identification of a primary target of thalidomide teratogenicity. Science 327: 1345-1350.
2. Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, et al. (2012) Cereblon is a direct target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 26: 2326-2335.
3. Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, et al. (2011) Cereblon expression is required for the anti-myeloma activity of lenalidomide and pomalidomide. Blood 118: 4771-4779.
4. Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, et al. (1999) Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 163: 380-386.
5. Schafer PH, Gandhi AK, Loveland MA, Chen RS, Man HW, et al. (2003) Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther 305: 1222-1232.
6. Galustian C, Meyer B, Labarthe MC, Dredge K, Klaschka D, et al. (2008) The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 58: 1033-1045.
7. Bartlett JB, Michael A, Clarke IA, Dredge K, Nicholson S, et al. (2004) Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br J Cancer 90: 955-961.
8. Smyth GK (2004) Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article 3.
9. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 57: 289-300.
10. R Development Core Team. (2012) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL Available: http://www.R-project.org/. Accessed May 10, 2013.
11. Galustian C, Meyer B, Labarthe MC, Dredge K, Klaschka D, et al. (2009) The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 58: 1033-1045.
12. Siena S, Van Cutsem E, Li M, Jungnelius U, Romano A, et al. (2013) Phase II, open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in patients with KRAS-mutant metastatic colorectal cancer. PLoS One 8: In press.
13. Ferrajoli A, Lee BN, Schlette EJ, O'Brien SM, Gao H, et al. (2008) Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 111: 5291-5297.
14. Hernandez-Ilizaliturri FJ, Reddy N, Holkova B, Ottman E, Czuczman MS (2005) Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res 11: 5984-5992.
15. Botta C, Bestoso E, Apollinari S, Cusi MG, Pastina P, et al. (2012) Immune-modulating effects of the newest cetuximab-based chemoimmunotherapy regimen in advanced colorectal cancer patients. J Immunother 35: 440-447.
16. Barbera-Guillem E, Nelson MB, Barr B, Nyhus JK, May KF Jr, et al. (2000) B lymphocyte pathology in human colorectal cancer. Experimental and clinical therapeutic effects of partial B cell depletion. Cancer Immunol Immunother 48: 541-549.
17. Streetly MJ, Gyertson K, Daniel Y, Zeldis JB, Kazmi M, et al. (2008) Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. Br J Haematol 141: 41-51.
18. Kneppers E, van der Holt B, Kersten MJ, Zweegman S, Meijer E, et al. (2011) Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial. Blood 118: 2413-2419.
19. Zhu D, Corral LG, Fleming YW, Stein B. (2008) Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol Immunother 57: 1849-1859.
20. Wu L, Adams M, Carter T, Chen R, Muller G, et al. (2008) Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res 14: 4650-4657.
21. Wu L, Adams M, Schafer P, Muller G, Stirling D, et al. (2008) Effect of lenalidomide and pomalidomide combined with IgG1-isotype antibodies on antibody-dependent cellular cytotoxicity (ADCC) via cytokine signaling and effector cell granzyme B and FasL expression. J Clin Oncol 26(Suppl 15): Abstract 3058.
22. Gandhi AK, Kang J, Capone L, Parton A, Wu L, et al. (2010) Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets 10: 155-167.
23. Hsu AK, Quach H, Tai T, Prince HM, Harrison SJ, et al. (2011) The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood 117: 1605-1613.